72 phenotypes from 7 alleles in 13 genetic backgrounds

Allelic Composition Genetic Background	Annotated Term	Reference
Acvrl1tm1Dgen/Acvrl1tm1Dgen involves: 129P2/OlaHsd * C57BL/6	abnormal aorta morphology	J:186473
	abnormal developmental vascular remodeling	J:186473
	abnormal dorsal aorta morphology	J:186473
	abnormal heart layer morphology	J:186473
	abnormal heart morphology	J:186473
	abnormal trabecula carnea morphology	J:186473
	abnormal visceral yolk sac morphology	J:186473
	abnormal vitelline vascular remodeling	J:186473
	abnormal vitelline vasculature morphology	J:186473
	embryonic growth retardation	J:186473
	embryonic lethality during organogenesis, complete penetrance	J:101679, J:186473
	enlarged heart	J:186473
	pericardial effusion	J:186473
	poor arterial differentiation	J:186473
Acvrl1tm1Dyl/Acvrl1+ involves: 129S1/Sv * 129X1/SvJ * C57BL/6J	no abnormal phenotype detected	J:65521, J:85366
Acvrl1tm1Dyl/Acvrl1tm1Dyl involves: 129S1/Sv * 129X1/SvJ * C57BL/6J	abnormal angiogenesis	J:65521
	abnormal anterior cardinal vein morphology	J:85366
	abnormal cardinal vein morphology	J:85366
	abnormal definitive hematopoiesis	J:65521, J:85366
	abnormal dorsal aorta morphology	J:85366
	abnormal vascular smooth muscle morphology	J:65521
	abnormal vitelline vascular remodeling	J:65521
	abnormal vitelline vasculature morphology	J:65521
	absent atrioventricular cushions	J:85366
	arteriovenous malformation	J:65521
	dilated dorsal aorta	J:85366
	embryonic growth arrest	J:65521
	embryonic lethality during organogenesis, complete penetrance	J:65521
	heart hypoplasia	J:85366
	increased vasodilation	J:85366
Acvrl1tm1Enl/Acvrl1+ B6.Cg-Acvrl1tm1Enl	abnormal cholinergic neuron morphology	J:226550
	abnormal circadian regulation of systemic arterial blood pressure	J:226550
	abnormal enzyme/coenzyme activity	J:226550
	abnormal physiological response to xenobiotic	J:226550
	abnormal sympathetic nervous system physiology	J:226550
	decreased circulating angiotensin II level	J:226550
	dilated brain ventricle	J:226550
	hypertension	J:226550
	increased circulating adrenaline level	J:226550
	increased circulating noradrenaline level	J:226550
	normal renal/urinary system phenotype	J:226550
Acvrl1tm1Enl/Acvrl1+ involves: C57BL/6	abnormal hepatobiliary system morphology	J:82115
	normal cardiovascular system phenotype	J:82115
	dilated liver sinusoidal space	J:82115
	enlarged liver	J:82115
	gastrointestinal hemorrhage	J:82115
	hemorrhage	J:82115
	premature death	J:82115
	telangiectasia	J:82115
Acvrl1tm1Enl/Acvrl1tm1Enl involves: C57BL/6	abnormal angiogenesis	J:61177
	abnormal blood vessel morphology	J:61177
	abnormal endocardium morphology	J:61177
	abnormal intersomitic vessel morphology	J:61177
	abnormal myocardium layer morphology	J:61177
	abnormal vascular smooth muscle morphology	J:61177
	abnormal vitelline vasculature morphology	J:61177
	arteriovenous malformation	J:61177
	dilated dorsal aorta	J:61177
	dilated pharyngeal arch artery	J:61177
	dilated vasculature	J:61177
	embryonic growth retardation	J:61177
	embryonic lethality during organogenesis, complete penetrance	J:61177
	enlarged pericardium	J:61177
	microcephaly	J:61177
Acvrl1tm1Spo/Acvrl1tm1Enl involves: 129S4/SvJae * C57BL/6	abnormal vascular development	J:85877
	embryonic lethality during organogenesis, complete penetrance	J:85877
Acvrl1tm1Spo/Acvrl1tm1Spo involves: 129S4/SvJae * C57BL/6	abnormal vascular development	J:85877
	embryonic lethality during organogenesis, complete penetrance	J:85877
Acvrl1tm1Spo/Acvrl1tm2Spo involves: 129 * 129S4/SvJae * C57BL/6	no abnormal phenotype detected	J:130020
Acvrl1tm2.1Spo/Acvrl1tm2.1Spo involves: 129	cerebral arteriovenous malformation	J:196810
Acvrl1tm2.1Spo/Acvrl1tm2.1Spo involves: 129 * C57BL/6 * FVB/N	no abnormal phenotype detected	J:130020
Acvrl1tm2.1Spo/Acvrl1tm2.1Spo Gt(ROSA)26Sortm1(cre/ERT)Nat/Gt(ROSA)26Sor+ involves: 129 * 129S1/Sv * 129X1/SvJ	abnormal lung vasculature morphology	J:154620
	anemia	J:154620
	arteriovenous malformation	J:154620
	cachexia	J:154620
	decreased hematocrit	J:154620
	enlarged heart	J:154620
	gastrointestinal arteriovenous malformation	J:154620
	internal hemorrhage	J:154620
	lung hemorrhage	J:154620
	melena	J:154620
	premature death	J:154620
Acvrl1tm2.1Spo/Acvrl1tm2.1Spo Tg(Acvrl1-cre)L1Spo/0 involves: 129 * FVB	abnormal blood vessel morphology	J:154620
	abnormal brain vasculature morphology	J:154620
	abnormal lung vasculature morphology	J:154620
	arteriovenous malformation	J:154620
	gastrointestinal hemorrhage	J:154620
	hemorrhage	J:154620
	lung hemorrhage	J:154620
	postnatal lethality	J:154620
	pulmonary arteriovenous malformation	J:154620
Acvrl1tm2.1Spo/Acvrl1tm2.1Spo Tg(Myh11-icre/ERT2)1Soff/0 involves: 129 * FVB/N	normal cardiovascular system phenotype	J:227170
Acvrl1tm2.1Spo/Acvrl1tm2.1Spo Tg(Tal1-cre/ERT)1Jrg/0 involves: 129 * C57BL/6	abnormal vascular wound healing	J:227170
	arteriovenous malformation	J:227170
	gastrointestinal arteriovenous malformation	J:227170
	large intestine hemorrhage	J:227170
	moribund	J:227170
Acvrl1tm2.2Spo/Acvrl1tm2.2Spo involves: 129 * C57BL/6 * FVB/N	absent vitelline blood vessels	J:130020
	embryonic growth retardation	J:130020
	embryonic lethality during organogenesis, complete penetrance	J:130020
	hemorrhage	J:130020
Acvrl1tm2Spo/Acvrl1tm2Spo Tg(Acvrl1-cre)L1Spo/0 involves: 129 * 129S4/SvJae * C57BL/6 * FVB/N	abnormal dorsal aorta morphology	J:130020
	abnormal lung vasculature morphology	J:130020
	abnormal vitelline vasculature morphology	J:130020
	arteriovenous malformation	J:130020
	dilated vasculature	J:130020
	lethality throughout fetal growth and development, complete penetrance	J:130020
	vascular smooth muscle hypotrophy	J:130020